Cargando…

The impact of Medicare part D on income-related inequality in pharmaceutical expenditure

BACKGROUND: Income-related inequality measures such as the concentration index are often used to describe the unequal distribution of health, health care access, or expenditure in a single measure. This study demonstrates the use of such measures to evaluate the distributional impact of changes in h...

Descripción completa

Detalles Bibliográficos
Autores principales: Carvalho, Natalie, Petrie, Dennis, Chen, Linkun, Salomon, Joshua A., Clarke, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469203/
https://www.ncbi.nlm.nih.gov/pubmed/30992000
http://dx.doi.org/10.1186/s12939-019-0955-9
_version_ 1783411599575351296
author Carvalho, Natalie
Petrie, Dennis
Chen, Linkun
Salomon, Joshua A.
Clarke, Philip
author_facet Carvalho, Natalie
Petrie, Dennis
Chen, Linkun
Salomon, Joshua A.
Clarke, Philip
author_sort Carvalho, Natalie
collection PubMed
description BACKGROUND: Income-related inequality measures such as the concentration index are often used to describe the unequal distribution of health, health care access, or expenditure in a single measure. This study demonstrates the use of such measures to evaluate the distributional impact of changes in health insurance coverage. We use the example of Medicare Part D in the United States, which increased access to prescription medications for Medicare beneficiaries from 2006. METHODS: Using pooled cross-sectional samples from the Medical Expenditure Panel Survey for 1997–2011, we estimated income-related inequality in drug expenditures over time using the concentration and generalised concentration indices. A difference-in-differences analysis investigated the change in inequality in drug expenditures, as measured using the concentration index and generalised concentration index, between the elderly (over 65 years) and near-elderly (54–63 years) pre- and post-implementation of Medicare Part D. RESULTS: Medicare Part D increased public drug expenditure while out-of-pocket and private spending fell. Public drug expenditures favoured the poor during all study periods, but the degree of pro-poorness declined in the years immediately following the implementation of Part D, with the poor gaining less than the rich in both relative and absolute terms. Part D also appeared to result in a fall in the pro-richness of private insurance drug expenditure in absolute terms but have minimal distributional impact on out-of-pocket expenditure. These effects appeared to be short lived, with a return to the prevailing trends in both concentration and generalised concentration indices several years following the start of Part D. CONCLUSIONS: The implementation of Medicare Part D significantly reduced the degree of pro-poorness in public drug expenditure. The poor gained less of the increased public drug expenditure than the rich in both relative and absolute terms. This study demonstrates how income-related inequality measures can be used to estimate the impact of health system changes on inequalities in health expenditure and provides a guide for future evaluations. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12939-019-0955-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6469203
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64692032019-04-23 The impact of Medicare part D on income-related inequality in pharmaceutical expenditure Carvalho, Natalie Petrie, Dennis Chen, Linkun Salomon, Joshua A. Clarke, Philip Int J Equity Health Research BACKGROUND: Income-related inequality measures such as the concentration index are often used to describe the unequal distribution of health, health care access, or expenditure in a single measure. This study demonstrates the use of such measures to evaluate the distributional impact of changes in health insurance coverage. We use the example of Medicare Part D in the United States, which increased access to prescription medications for Medicare beneficiaries from 2006. METHODS: Using pooled cross-sectional samples from the Medical Expenditure Panel Survey for 1997–2011, we estimated income-related inequality in drug expenditures over time using the concentration and generalised concentration indices. A difference-in-differences analysis investigated the change in inequality in drug expenditures, as measured using the concentration index and generalised concentration index, between the elderly (over 65 years) and near-elderly (54–63 years) pre- and post-implementation of Medicare Part D. RESULTS: Medicare Part D increased public drug expenditure while out-of-pocket and private spending fell. Public drug expenditures favoured the poor during all study periods, but the degree of pro-poorness declined in the years immediately following the implementation of Part D, with the poor gaining less than the rich in both relative and absolute terms. Part D also appeared to result in a fall in the pro-richness of private insurance drug expenditure in absolute terms but have minimal distributional impact on out-of-pocket expenditure. These effects appeared to be short lived, with a return to the prevailing trends in both concentration and generalised concentration indices several years following the start of Part D. CONCLUSIONS: The implementation of Medicare Part D significantly reduced the degree of pro-poorness in public drug expenditure. The poor gained less of the increased public drug expenditure than the rich in both relative and absolute terms. This study demonstrates how income-related inequality measures can be used to estimate the impact of health system changes on inequalities in health expenditure and provides a guide for future evaluations. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12939-019-0955-9) contains supplementary material, which is available to authorized users. BioMed Central 2019-04-16 /pmc/articles/PMC6469203/ /pubmed/30992000 http://dx.doi.org/10.1186/s12939-019-0955-9 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Carvalho, Natalie
Petrie, Dennis
Chen, Linkun
Salomon, Joshua A.
Clarke, Philip
The impact of Medicare part D on income-related inequality in pharmaceutical expenditure
title The impact of Medicare part D on income-related inequality in pharmaceutical expenditure
title_full The impact of Medicare part D on income-related inequality in pharmaceutical expenditure
title_fullStr The impact of Medicare part D on income-related inequality in pharmaceutical expenditure
title_full_unstemmed The impact of Medicare part D on income-related inequality in pharmaceutical expenditure
title_short The impact of Medicare part D on income-related inequality in pharmaceutical expenditure
title_sort impact of medicare part d on income-related inequality in pharmaceutical expenditure
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469203/
https://www.ncbi.nlm.nih.gov/pubmed/30992000
http://dx.doi.org/10.1186/s12939-019-0955-9
work_keys_str_mv AT carvalhonatalie theimpactofmedicarepartdonincomerelatedinequalityinpharmaceuticalexpenditure
AT petriedennis theimpactofmedicarepartdonincomerelatedinequalityinpharmaceuticalexpenditure
AT chenlinkun theimpactofmedicarepartdonincomerelatedinequalityinpharmaceuticalexpenditure
AT salomonjoshuaa theimpactofmedicarepartdonincomerelatedinequalityinpharmaceuticalexpenditure
AT clarkephilip theimpactofmedicarepartdonincomerelatedinequalityinpharmaceuticalexpenditure
AT carvalhonatalie impactofmedicarepartdonincomerelatedinequalityinpharmaceuticalexpenditure
AT petriedennis impactofmedicarepartdonincomerelatedinequalityinpharmaceuticalexpenditure
AT chenlinkun impactofmedicarepartdonincomerelatedinequalityinpharmaceuticalexpenditure
AT salomonjoshuaa impactofmedicarepartdonincomerelatedinequalityinpharmaceuticalexpenditure
AT clarkephilip impactofmedicarepartdonincomerelatedinequalityinpharmaceuticalexpenditure